Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis Compared to Lucentis Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration

Next Previous
X
Search
Trial Profile

A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis Compared to Lucentis Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegpleranib (Primary) ; Ranibizumab
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Sponsors IVERIC bio

    • Most Recent Events

    • 19 Dec 2016 Status changed from active, no longer recruiting to discontinued.
    • 12 Dec 2016 Results of a pooled analysis from OPH1002 and OPH1003 trials published in an OphthoTech Corporation Media Release
    • 12 Dec 2016 According to a Novartis media release, data from this and another (OPH1003) studies, including secondary and exploratory efficacy endpoints, will be presented at a future medical meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top